In anti-PD-1 group, patients with BRAF or NRAS mutations had poorer DFS...no survival benefits were found for patients with BRAF, NRAS, or KIT mutations....Although anti-PD-1 adjuvant therapy provides a better DFS in the general population and in wild-type patients, patients with BRAF, KIT or, especially, NRAS mutation may not benefit further from immunotherapy than conventional IFN treatment or observation.